OTC Markets OTCPK - Delayed Quote USD

Telix Pharmaceuticals Limited (TLPPF)

Compare
14.40 0.00 (0.00%)
At close: October 22 at 4:00 PM EDT
Loading Chart for TLPPF
DELL
  • Previous Close 14.79
  • Open 14.79
  • Bid 14.00 x 40000
  • Ask 14.20 x 40000
  • Day's Range 14.79 - 14.79
  • 52 Week Range 5.55 - 15.40
  • Volume 250
  • Avg. Volume 5,208
  • Market Cap (intraday) 4.819B
  • Beta (5Y Monthly) 2.40
  • PE Ratio (TTM) 144.00
  • EPS (TTM) 0.10
  • Earnings Date Aug 22, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

telixpharma.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TLPPF

View More

Performance Overview: TLPPF

Trailing total returns as of 10/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TLPPF
109.45%
S&P/ASX 200 [XJO]
8.05%

1-Year Return

TLPPF
166.52%
S&P/ASX 200 [XJO]
19.62%

3-Year Return

TLPPF
215.10%
S&P/ASX 200 [XJO]
10.61%

5-Year Return

TLPPF
1,152.17%
S&P/ASX 200 [XJO]
22.53%

Compare To: TLPPF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TLPPF

View More

Valuation Measures

Annual
As of 10/22/2024
  • Market Cap

    4.68B

  • Enterprise Value

    4.62B

  • Trailing P/E

    144.25

  • Forward P/E

    62.11

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.10

  • Price/Book (mrq)

    17.77

  • Enterprise Value/Revenue

    10.89

  • Enterprise Value/EBITDA

    95.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.62%

  • Return on Assets (ttm)

    7.97%

  • Return on Equity (ttm)

    20.49%

  • Revenue (ttm)

    645.68M

  • Net Income Avi to Common (ttm)

    49.19M

  • Diluted EPS (ttm)

    0.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    118.84M

  • Total Debt/Equity (mrq)

    5.48%

  • Levered Free Cash Flow (ttm)

    105.93M

Company Insights: TLPPF

People Also Watch